Repligen Corporation (NASDAQ:RGEN) Receives $166.43 Average PT from Analysts

Repligen Corporation (NASDAQ:RGEN) has earned a consensus rating of “Buy” from the eighteen analysts that are presently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation, twelve have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $166.4286.

RGEN has been the subject of several analyst reports. Royal Bank Of Canada began coverage on Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price for the company. Citigroup upgraded Repligen to a “buy” rating in a report on Tuesday, July 7th. Wells Fargo & Company lifted their price target on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Benchmark upgraded shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a research note on Tuesday, July 7th. Finally, Evercore restated an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th.

Insider Buying and Selling

In related news, CFO Jason Garland sold 733 shares of Repligen stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Repligen

Several hedge funds and other institutional investors have recently made changes to their positions in the business. ABS Investment Management LLC bought a new position in shares of Repligen in the second quarter worth about $191,016,000. Measured Wealth Private Client Group LLC acquired a new stake in Repligen in the 3rd quarter valued at approximately $29,000. Los Angeles Capital Management LLC acquired a new stake in Repligen in the 4th quarter valued at approximately $36,000. Farther Finance Advisors LLC increased its position in Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after buying an additional 128 shares during the period. Finally, Itau Unibanco Holding S.A. increased its position in Repligen by 38.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after buying an additional 104 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Repligen Price Performance

NASDAQ RGEN opened at $167.60 on Friday. Repligen has a fifty-two week low of $100.99 and a fifty-two week high of $188.73. The stock’s 50-day moving average is $155.54 and its two-hundred day moving average is $134.24. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The firm has a market cap of $9.46 billion, a P/E ratio of 229.59, a price-to-earnings-growth ratio of 3.06 and a beta of 1.05.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business’s quarterly revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, analysts anticipate that Repligen will post 2.06 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.